EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

Bladder cancer is a biologically heterogeneous disease, and its classification plays a critical role in guiding treatment. However, current bladder cancer classification remains based primarily on clinical-pathological features or staging, with molecular subtyping yet to be standardized. At the 2025 European Association of Urology (EAU) Congress, Dr. Jeffrey S. Damrauer from the UNC Lineberger Comprehensive Cancer Center shared key insights on the response of different bladder cancer types to treatment, the role of neoadjuvant therapy, and the growing possibilities of bladder-sparing strategies.
EAU 2025丨Dr. Siamak Daneshmand Shares the Potential of Oncolytic Virus Therapy for NMIBC Patients

EAU 2025丨Dr. Siamak Daneshmand Shares the Potential of Oncolytic Virus Therapy for NMIBC Patients

For patients with non-muscle-invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) therapy, clinicians and researchers are actively exploring novel treatment strategies. Among these, oncolytic virus therapy has emerged as a promising approach. At the 40th Annual EAU Congress, Dr. Siamak Daneshmand from the University of Southern California (USC) presented two key studies on oncolytic viruses—the BOND-003 P cohort and the PIVOT-006 trial. UroStream invited Professor Daneshmand to discuss the mechanism of action, safety, efficacy, and future directions of this innovative therapy.
EAU 2025 | Non-Invasive Evaluation of Tumor Heterogeneity in BCR: Professor Xuefeng Qiu Shares Advancements and Clinical Experience with PSMA-PET/CT at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University

EAU 2025 | Non-Invasive Evaluation of Tumor Heterogeneity in BCR: Professor Xuefeng Qiu Shares Advancements and Clinical Experience with PSMA-PET/CT at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University

In recent years, prostate-specific membrane antigen (PSMA) molecular imaging technology has demonstrated significant value in the diagnosis and treatment of prostate cancer. It has improved the accuracy of clinical staging, supported multimodal treatment decision-making, and facilitated the development of precision medicine through novel radioligand therapies. At the recent EAU Congress, UroStream invited Professor Xuefeng Qiu from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, to share insights into his team’s research on PSMA PET/CT for predicting biochemical recurrence (BCR), the impact of tumor heterogeneity, and the clinical experience at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University.
Professor Michael Gnant, SGBCC President, Visits The Second Hospital of Dalian Medical University for Academic Exchange on Cutting-Edge Breast Cancer Diagnosis and Treatment

Professor Michael Gnant, SGBCC President, Visits The Second Hospital of Dalian Medical University for Academic Exchange on Cutting-Edge Breast Cancer Diagnosis and Treatment

The St. Gallen International Breast Cancer Conference (SGBCC) is one of the most authoritative and influential global events in the field of breast cancer, dedicated to advancing standardized diagnosis and treatment for early-stage breast cancer. To integrate international frontier concepts with domestic clinical practice and align China’s breast cancer care with global standards—ultimately delivering superior treatment options for patients—Professor Michael Gnant, President of SGBCC, visited The Second Hospital of Dalian Medical University on April 9 for a two-day academic exchange and collaboration initiative.